STXS

Company Overview — What Does Stereotaxis, Inc. Do?

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was incorporated in 1990 and is headquartered in Saint Louis, Missouri. Stereotaxis, Inc. (STXS) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO David L. Fischel and employs approximately 130 people, headquartered in ST.LOUIS, Missouri. With a market capitalization of $180M, STXS is one of the notable companies in the Healthcare sector.

Stereotaxis, Inc. (STXS) Stock Rating — Avoid (April 2026)

As of April 2026, Stereotaxis, Inc. receives a Avoid rating with a composite score of 29.1/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.STXS ranks #3,934 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Stereotaxis, Inc. ranks #674 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

STXS Stock Price and 52-Week Range

Stereotaxis, Inc. (STXS) currently trades at $1.87. The stock lost $0.08 (4.1%) in the most recent trading session. The 52-week high for STXS is $3.59, which means the stock is currently trading -47.9% from its annual peak. The 52-week low is $1.54, putting the stock 21.4% above its annual trough. Recent trading volume was 557K shares, suggesting relatively thin trading activity.

Is STXS Overvalued or Undervalued? — Valuation Analysis

Stereotaxis, Inc. (STXS) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 13.38x, versus the sector average of 2.75x. The price-to-sales ratio is 5.48x, compared to 1.66x for the average Healthcare stock.

At current multiples, Stereotaxis, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Stereotaxis, Inc. Profitability — ROE, Margins, and Quality Score

Stereotaxis, Inc. (STXS) earns a quality factor score of 21/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -165.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -42.7% versus the sector average of -33.1%.

On a margin basis, Stereotaxis, Inc. reports gross margins of 51.5%, compared to 71.5% for the sector. The operating margin is -70.3% (sector: -66.1%). Net profit margin stands at -68.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 65.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

STXS Debt, Balance Sheet, and Financial Health

Stereotaxis, Inc. has a debt-to-equity ratio of 249.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.51x, suggesting adequate working capital coverage.

STXS has a beta of 1.25, meaning it is more volatile than the broader market — a $10,000 investment in STXS would be expected to move 24.6% more than the S&P 500 on any given day. The stability factor score for Stereotaxis, Inc. is 41/100, reflecting average volatility within the normal range for its sector.

Stereotaxis, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Stereotaxis, Inc. reported revenue of $33M and earnings per share (EPS) of $-0.25. Net income for the quarter was $-22M. Gross margin was 51.5%. Operating income came in at $-23M.

In FY 2025, Stereotaxis, Inc. reported revenue of $32M and earnings per share (EPS) of $-0.25. Net income for the quarter was $-22M. Gross margin was 52.7%. Revenue grew 20.3% year-over-year compared to FY 2024. Operating income came in at $-22M.

In Q3 2025, Stereotaxis, Inc. reported revenue of $7M and earnings per share (EPS) of $-0.07. Net income for the quarter was $-6M. Gross margin was 54.9%. Revenue grew -18.8% year-over-year compared to Q3 2024. Operating income came in at $-7M.

In Q2 2025, Stereotaxis, Inc. reported revenue of $9M and earnings per share (EPS) of $-0.05. Net income for the quarter was $-4M. Gross margin was 52.0%. Revenue grew 95.4% year-over-year compared to Q2 2024. Operating income came in at $-4M.

Over the past 8 quarters, Stereotaxis, Inc. has demonstrated a growth trajectory, with revenue expanding from $5M to $33M. Investors analyzing STXS stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

STXS Dividend Yield and Income Analysis

Stereotaxis, Inc. (STXS) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

STXS Momentum and Technical Analysis Profile

Stereotaxis, Inc. (STXS) has a momentum factor score of 31/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 52/100 reflects moderate short selling activity.

STXS vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Stereotaxis, Inc. (STXS) ranks #674 out of 838 stocks based on the Blank Capital composite score. This places STXS in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing STXS against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full STXS vs S&P 500 (SPY) comparison to assess how Stereotaxis, Inc. stacks up against the broader market across all factor dimensions.

STXS Next Earnings Date

No upcoming earnings date has been announced for Stereotaxis, Inc. (STXS) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy STXS? — Investment Thesis Summary

The quantitative profile for Stereotaxis, Inc. suggests caution. The quality score of 21/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Momentum is weak at 31/100, a headwind for near-term performance.

In summary, Stereotaxis, Inc. (STXS) earns a Avoid rating with a composite score of 29.1/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on STXS stock.

Related Resources for STXS Investors

Explore more research and tools: STXS vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare STXS head-to-head with peers: STXS vs AZN, STXS vs SLGL, STXS vs VMD.